Department of Radiation Oncology, Xiamen Cancer Hospital, the First Affiliated Hospital of Xiamen University, Xiamen 361003, PR China.
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, PR China.
Future Oncol. 2019 Feb;15(5):507-516. doi: 10.2217/fon-2018-0677. Epub 2018 Oct 31.
To assess the outcomes of breast cancer subtype in inflammatory breast cancer (IBC).
We retrospectively assessed IBC patients from the SEER program.
We identified 626 patients, including 230 (36.7%),100 (17.6%), 113 (18.1%), and 173 (27.6%) patients with HoR+/HER2-, HoR+/HER2+, HoR-/HER2+, and HoR-/HER2- subtype disease, respectively. Multivariate analysis demonstrated that, using HoR+/HER2- subtype as reference, patients with HoR+/HER2+ subtype had better breast cancer-specific survival (BCSS) and overall survival (OS), and patients with HoR-/HER2- subtype had worse BCSS and OS, while BCSS and OS were comparable for HoR-/HER2+ subtype. Similar trends were observed in patients who received surgery, radiotherapy, chemotherapy or trimodality therapy.
Breast cancer subtype is clinically useful for predicting survival outcome in IBC. The HoR+/HER2- subtype shows poorer survival outcome than HoR+/HER2+ subtype.
评估炎性乳腺癌（IBC）中乳腺癌亚型的结局。
我们从 SEER 计划中回顾性评估了 IBC 患者。
我们共识别出 626 名患者，分别包括 HoR+/HER2-、HoR+/HER2+、HoR-/HER2+和 HoR-/HER2-亚型疾病的 230（36.7%）、100（17.6%）、113（18.1%）和 173（27.6%）名患者。多变量分析表明，与 HoR+/HER2-亚型相比，HoR+/HER2+亚型患者的乳腺癌特异性生存（BCSS）和总生存（OS）更好，而 HoR-/HER2-亚型患者的 BCSS 和 OS 更差，而 HoR-/HER2+亚型的 BCSS 和 OS 则相似。在接受手术、放疗、化疗或三联疗法的患者中也观察到了类似的趋势。
乳腺癌亚型对预测 IBC 的生存结局具有临床意义。HoR+/HER2-亚型的生存结果比 HoR+/HER2+亚型差。
